Cancer Summaries and Commentaries™: Report from Orlando on Advances in the Treatment of CLL

Release Date: December 24, 2019
Expiration Date: December 24, 2020
Media: Internet - based

Activity Overview

This online activity is designed to update physicians on data presented at the American Society of Hematology Annual Meeting, held in December 2019 in Orlando, Florida. The Cancer Summaries and Commentaries™: Report from Orlando on Advances in the Treatment of CLL online continuing medical education (CME) activity facilitates critical assessment and clinical integration of new evidence, when appropriate. The activity reviews 6 abstracts with the most recent and clinically pertinent chronic lymphocytic leukemia (CLL) presentations from the meeting. For each abstract, a short summary introduction, study design, key clinical data, and a conclusion is accompanied by expert perspectives that provide insight into how clinicians can apply these findings to their clinical practice to improve patient care.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from AstraZeneca.

Target Audience

This activity is directed toward medical oncologists and hematologists who are interested in the treatment of CLL. Fellows, nurses, nurse practitioners, physician assistants, and other healthcare professionals involved in the management of patients with CLL will also be invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

• Outline novel treatment options exploring targeted therapies, immunotherapies, and combination therapies in patients with CLL
• Explain the study design, rationale, and results of recent clinical trials evaluating novel strategies for the treatment of CLL
• Consider best practices to apply novel treatment strategies for the treatment of patients with CLL

Faculty, Staff, and Planners’ Disclosures

Faculty

Ian Flinn, MD, PhD
Director of Lymphoma Research Program
Sarah Cannon Research Institute
Nashville, TN

Disclosures: Consultant: AbbVie, Seattle Genetics, TG Therapeutics, Verastem; Research Funding: AbbVie, Acerta, Agios, ArQule, BeiGene, Calithera, Celgene, Constellation, Curis, Forma, Forty-Seven, Genentech, Gilead, Incyte, Infinity, Janssen, Karyopharm, KITE, MERCK, Novartis, Pfizer, Pharmacyclics, Portola, Roche, Seattle Genetics, Takeda, Teva, TG Therapeutics, Trillium, Verastem.

Susan O’Brien, MD
Associate Director for Clinical Sciences
Chao Family Comprehensive Cancer Center
Medical Director
Stern Center for Cancer Clinical Trials and Research
Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
University of California – Irvine
Irvine, CA

Disclosures: Consultant: Amgen, Astellas, Celgene, GlaxoSmithKline, Janssen Oncology, Aptose Biosciences Inc., Vaniam Group LLC, AbbVie, Alexion, Verastem, Eisai; Research Support: Kite, Regeneron, Acerta; Consultant/Research Support: Gilead, Pharmacyclics, TG Therapeutics, Pfizer, Sunesis.

The staff of Physicians' Education Resource^®, LLC (PER^®) have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER^® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER^® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER^® is required by ACCME to resolve all COI. PER^® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^®.